Novel Insights into the Potential Diagnostic Value of Circulating Exosomal IncRNA-Related Networks in Large Artery Atherosclerotic Stroke

Shuai Zhang¹, Jing Wang¹, Mei Jie Qu¹, Kun Wang¹, Ai Jun Ma¹,²*, Xu Dong Pan¹,²* and Xiao Yan Zhu³*

¹Department of Neurology, The Affiliated Hospital of Qingdao University, Qingdao, China, ²Institute of Cerebrovascular Diseases, The Affiliated Hospital of Qingdao University, Qingdao, China, ³Department of Critical Care Medicine, The Affiliated Hospital of Qingdao University, Qingdao, China

Exosomes show diagnostic and therapeutic promise as carriers of ncRNAs in diseases. LncRNAs in exosomes have been identified as being stable and avoided degradation by nucleolytic enzymes. Although IncRNAs have been confirmed to be important in cancers, no studies for exo-IncRNAs have been reported in LAA stroke. High-throughput sequencing was performed to detect the differential expression profiles of IncRNAs in five paired plasma-derived exosome samples from patients with LAA stroke and controls (matched on vascular risk factors). Exo-IncRNA-associated networks were predicted with a combination of multiple databases. The expression of the selected genes in the networks was confirmed by qRT-PCR in a validation set (LAA vs. controls = 30:30). Furthermore, ROC analysis was used to evaluate the diagnostic performance of the IncRNA-related networks. A total of 1,020 differentially expressed IncRNAs were identified in LAA stroke patients. GO and KEGG pathway analyses indicated that their target genes are involved in atherosclerosis-related pathways, including inflammation, cell adhesion, and cell migration. qRT-PCR confirmed that the expression trend of differentially expressed genes was consistent with RNA-seq. Furthermore, the AUCs of the Inc_002015-related network and Inc_001350-related network were 0.959 and 0.97, respectively, in LAA stroke. Our study showed the differential expression of IncRNAs in plasma exosomes and presented related diagnostic networks for LAA stroke for the first time. The results suggested that exosomal IncRNA-related networks could be potential diagnostic tools in LAA stroke.

Keywords: large artery atherosclerotic stroke, exosome, long noncoding RNA, diagnostic performance, RNA sequencing

Abbreviations: LAA stroke, large artery atherosclerotic stroke; GEO, gene expression omnibus; DEGs, differentially expressed genes; PPI, protein–protein interactions; KEGG, Kyoto encyclopedia of genes and genomes; Exo-IncRNA, exosomal IncRNA; ROC, receiver operating characteristic curve; AUC, area under curve.
INTRODUCTION

Stroke, the second leading cause of global mortality (Chen et al., 2017; Zhang et al., 2020), is also widely known for its high disability rate. Large artery atherosclerotic (LAA) stroke, classified according to the Trial of Org 10,172 in Acute Stroke Treatment (TOAST) system, is the most common type of stroke (Adams et al., 1993; Huang et al., 2017). LAA stroke has the highest rates of recurrence and death among all stroke subtypes (Murat Sumer et al., 2002). Thrombolytic therapy plays an important role in the treatment of ischemic stroke, but it has a strict time window (Lansberg et al., 2009; Sidorov et al., 2019). Thus, a rapid and accurate blood test for LAA stroke would be valuable. Increasing studies have verified that exosomes, as a form of communication between cells, have promise for diagnosis and treatment in cancer and neurodegenerative diseases (Zheng et al., 2019; Khalyfa et al., 2020; Jia et al., 2021).

Exosomes, 30–150 nm in size, are formed by the invagination of intracellular lysosome particles and their fusion with the cell membrane (Al-Nedawi et al., 2008). When exosomes are incorporated into recipient cells, their contents, such as RNA molecules (e.g., lncRNAs, circRNAs, miRNAs, mRNAs), proteins and lipids, are released into recipient cells, thus acting as a type of cell-cell communication (Al-Nedawi et al., 2008; Jeppesen et al., 2019). These different cargos make exosomes to be unique candidates of noninvasive diagnostic indicators. Evidence has shown that lncRNA can be protected from degradation by exosomes, which increases the stability of lncRNAs in plasma (Guo et al., 2020; Kim et al., 2020). A previous study verified that in hepatocellular carcinoma, circulating lncRNA-GC1 molecules were almost all packaged in exosomes and thereby protected, ensuring sufficient stability of lncRNA-GC1 in clinical tests (Lu et al., 2020). Thus, exosomes could be potential targets for exploring the diagnostic and regulatory mechanisms of lncRNAs.

LncRNAs, which are transcribed sequences longer than 200 nucleotides, have been recognized and proven to be important participants in biological functions, such as inflammation, immunity and autophagy (Serghiou et al., 2016; Robinson et al., 2020). LncRNAs have a variety of regulatory functions, and the ceRNA network regulatory mechanism is one of the most important posttranscriptional regulation mechanisms in the cytoplasm (Cesana et al., 2011). Existing studies have found that lncRNAs can competitively bind miRNAs, thus influencing the regulation of downstream target mRNAs by miRNAs (Qu et al., 2016; Huang et al., 2019). Recently, Dykstra-Aiello et al. suggested that lncRNAs might be included with miRNAs and mRNAs as possible diagnostic indicators in stroke (Dykstra-Aiello et al., 2016). However, no studies have assessed the potential diagnostic value of exo-lncRNA-related networks.

In general, this study aimed to explore the differential expression profiles of exo-lncRNAs and construct exo-lncRNA-related networks, which might be evaluated for their potential utility in the accurate diagnosis of LAA stroke. Our results may provide a novel perspective on exo-lncRNA-related networks for the diagnosis and understanding of the mechanism of LAA stroke.

MATERIALS AND METHODS

Study Population Enrollment

Our study enrolled 35 LAA stroke patients (LAA group) and 35 healthy persons (control group) at the Affiliated Hospital of Qingdao University from March 2020–October 2020. The discovery samples included 5 patients and 5 healthy controls. Validation was performed in 30 patients and 30 healthy controls. All samples were matched on age, sex, and vascular risk factors (VRFs) including hypertension, diabetes mellitus, smoking and drinking.

LAA stroke patients (LAA group) were included in the study according to the TOAST standards (Adams et al., 1993). Inclusion criteria were as follows: ischemic stroke within 72 h of onset; age ≥ 18 years; underwent brain MRI, brain MRA or CTA examination and echocardiography; and the stenosis rate of extracranial or intracranial arteries was more than 50%. The correlation between the degree of atherosclerosis and stroke was determined by experienced neuroscientists. Exclusion criteria included: nonatherosclerotic intracranial stenosis (e.g., moyamoya disease, vasculitis, or anatomy), potential sources of cardiac embolism (e.g., atrial fibrillation), incomplete cerebrovascular condition examination, and tumor or severe liver and kidney dysfunction (Feng et al., 2019; Shen et al., 2019). This study was approved by the Ethics Committee of The Affiliated Hospital of Qingdao University.

Blood Collection Exosome Isolation

Peripheral blood samples (6 ml) were collected in EDTA tubes. After centrifugation at 3,000 × g at 4°C for 15 min, at least 3 ml plasma was collected and stored at −80°C. After thawing at 37°C, the plasma was centrifuged at 2,000 × g for 20 min, and the supernatant was obtained. The debris was centrifuged again at 10,000 × g for 20 min. Then, Total Exosome Isolation (from plasma) reagent (Invitrogen, 4484450, California, United States) (Lobb, et al., 2015) was used according to the manufacturer’s instructions. Briefly, protease K (0.05 times the volume of plasma) was added to the plasma and incubated at 37°C for 10 min. Then, 0.2 volumes of exosome extraction reagent were added to the mixture and incubated at 4°C for 30 min. The mixture was centrifuged at 10,000 × g at room temperature for 5 min. The exosomes, contained in a pellet at the bottom of the tube, were resuspended in PBS and stored at −80°C.

Identification of Plasma Exosomes

Identification of Exosomes by Nanoparticle Tracking Analysis

Exosome samples were resuspended in 1 ml of 1 × PBS and examined using a Zeta View PMX 110 (Particle Metrix, Meerbusch, Germany) equipped with a 405 nm laser to determine the size and quantity of particles (Zhan et al., 2018). Particle movement was assessed by NTA software (ZetaView 8.02.28).

Observation of Exosomes by Transmission Electron Microscopy

Exosome suspension (20 µL) was deposited on a copper grid for 10 min at room temperature, and then washed with sterile...
distilled water. The exosomes were negatively stained with 2% uranyl acetate solution for 1 min and dried for a few minutes at room temperature. The samples were observed and photographed under a transmission electron microscopy (Zhan et al., 2018) (TEM, Hitachi, Tokyo, Japan).

**Analysis of Exosomes by Western Blot**
Exosomes were lyzed in cold standard RIPA buffer with PMSF (MCE, United States). The total protein concentration was determined by BCA assay. Protein samples (25 ug/lane) were added to 10% SDS polyacrylamide gels and then transferred to PVDF membranes (Millipore Co., NJ, United States of America). Plasma exosomes were identified using three positive markers, CD9, CD63, and TSG101 (Abcam, MA, United States), and one negative marker, GRP94 (Abcam, MA, United States) (Cordonnier et al., 2020). The blots were detected by a chemiluminescence system (United States) and analyzed by Quantity One.

**RNA Extraction and Quality Assessment**
Total exosomal RNA was isolated by the miRNeasy Serum/Plasma Advanced Kit (Qiagen, cat. 217,204, Germany); specific procedures were performed according to the company’s operation manual. RNA purity was checked using a Nanophotometer® spectrophotometer (IMPLEN, CA, United States). RNA concentration was measured using a Qubit® RNA Assay Kit in a Qubit® 2.0 Fluorometer (Life Technologies, United States). RNA integrity was assessed using the RNA Nano 6000 Assay Kit of the Bioanalyzer 2,100 system (Agilent Technologies, CA, United States).

**Library Construction and Sequencing**
The libraries were constructed and sequenced by Novogene (Beijing, China) (Tian et al., 2020). Briefly, a total amount of 20 ng RNA per sample was used as the RNA sample for preparation. Ribosomal RNA was removed by an Epicenter Ribo-zero™ rRNA Removal Kit (Epicenter, United States). The sequencing libraries were generated using RNA-depleted RNA by the NEBNext® Ultra™ Directional RNA Library Prep Kit for Illumina® (NEB, United States), following the manufacturer’s recommendations. Briefly, first strand cDNA was synthesized using random hexamer primers and M-MuLV Reverse Transcriptase (RNaseH). Second-strand cDNA synthesis was subsequently performed using DNA Polymerase I and RNase H. Then, PCR was performed with Phusion High-Fidelity DNA polymerase, universal PCR primers and Index (X) Primer. Finally, the products were purified (AMPure XP system), and the library quality was assessed on the Agilent Bioanalyzer 2,100 system. The libraries were sequenced on an Illumina HiSeq 2,500 platform, and 125 bp paired-end reads were generated.

**Analysis and Screening of IncRNA, miRNA and mRNA Data**
Raw data (raw reads) in FASTQ format were first processed through in-house Perl scripts to obtain clean data (clean reads). At the same time, the Q20, Q30, and GC contents of the clean data were calculated. All downstream analyses were based on clean data with high quality. We obtained eligible transcripts through matching, assembly, screening and evaluation. String Tie (v2.1.1) was used to calculate the FPKMs of both IncRNAs and coding transcripts in each sample.

The reads obtained from the above steps were assessed using the Ballgown suite, Cufflinks and edgeR. Transcripts with \[\log_{2}\text{fold change} \geq 2\] (IncRNA, mRNA) or 1 (miRNA) and \(p < 0.05\) were assigned as differentially expressed. The results were visualized by volcano maps and heat maps prepared using the R package (R-3.3.3) and TBtools.

**PPI Network and Module Analysis of DE mRNAs**
PPI analysis of the differential expressed (DE) mRNAs was performed based on the STRING database. Then, the submodules were selected from the PPI network with a cutoff score = 2.5 by the Molecular Complex Detection (MCODE) plugin. The results were visualized by Cytoscape (Cytoscape-3.7.2).

**GO and KEGG Enrichment Analysis**
The DAVID database and KOBASE database were used to infer the potential functions of the DE mRNAs in terms of biological process (BP), cellular component (CC), and molecular function (MF) GO annotations and KEGG pathways. R package tools were used to visualize the results.

**Prediction of Subcellular Localization of IncRNAs**
The regulatory pattern of IncRNAs is largely dependent on their subcellular localization. The IncLocator website and iLoc-LncRNA website are useful tools for obtaining predictions of subcellular localization. A high prediction score indicates that the searched IncRNA localizes mostly to the cytoplasm. The exo-IncRNAs of interest (selection criteria according to the fold change, function of differential expressed genes and reads in each sample, the details of the data were shown in Online Supplementary Tables S1, S4, S5) were predicted, which further confirmed the IncRNA-related molecular interaction sites.

**Construction of IncRNA-related Networks**
We used the R “cor.test” package to calculate the correlation between DE IncRNAs and DE mRNAs, based on the expression levels of the genes. A correlation coefficient (Spearman correlation analysis) > 0.85 and a \(p < 0.05\) were considered to indicate coexpression. LncRNAs can act as sponges by binding with the “seed” region of miRNAs. Based on TargetScan, RNAhybrid and miRanda analyses, the binding sites of miRNA-DE IncRNAs and miRNA-DE mRNAs were predicted. The same miRNA binding sites were selected. The parameters used in miRanda were \(S > 150\) and \(\Delta G < -30\) kcal/mol. \(S\) represents the number of matching bases, and \(\Delta G\) is the binding free energy of the paired sequence. The correlation coefficient between the miRNA and IncRNA or mRNA was calculated, and pairs with negative correlations were selected. The IncRNAs of interest were screened based on the target gene functions and differential expression to identify hub IncRNAs.
TABLE 1 | Primer sequences in the study.

| Genes      | 5’-3’ Primer sequences                     |
|------------|--------------------------------------------|
| Inc_00048  | Forward TGGGACGTTTGAGTGATTTGCTGAGG        |
| Inc_001346 | Reverse GGTGATTTGTAGTGTTGCTGAGG           |
| Inc_001347 | Forward TGCAAGTGAGTGATTTGCTGAGG           |
| Inc_001350 | Reverse CCACTTCACTGCTGCTGAGG              |
| Inc_002015 | Forward CCCGTCACTGCTGCTGAGG               |
| Inc_012006 | Reverse CCACTTCACTGCTGCTGAGG              |
| Inc_013144 | Forward CCCGTCACTGCTGCTGAGG               |
| Inc_016442 | Reverse CCCGTCACTGCTGCTGAGG               |
| AACS       | Forward GGTTAGTGCAGTTGAGTGATTTGCTGAGG    |
| AAMP       | Reverse CCACTTCACTGCTGCTGAGG              |
| ABCA3      | Forward CCCGTCACTGCTGCTGAGG               |
| GADD45G    | Reverse CCACTTCACTGCTGCTGAGG              |
| JUNB       | Forward CCCGTCACTGCTGCTGAGG               |
| PTPRC      | Reverse CCACTTCACTGCTGCTGAGG              |
| ST14       | Forward CCCGTCACTGCTGCTGAGG               |
| U6         | Forward CCCGTCACTGCTGCTGAGG               |
| Hsa-miR-328| Forward CCCGTCACTGCTGCTGAGG               |
| Hsa-miR-342| Forward CCCGTCACTGCTGCTGAGG               |
| Hsa-miR-1273| Forward CCCGTCACTGCTGCTGAGG              |
| Hsa-miR-1538| Forward CCCGTCACTGCTGCTGAGG              |
| Hsa-miR-1908| Forward CCCGTCACTGCTGCTGAGG              |
| Hsa-miR-3127| Forward CCCGTCACTGCTGCTGAGG              |

Validation of RNA-seq Results by Quantitative Real-Time Polymerase Chain Reaction

qRT-PCR was used to verify the DE hub IncRNAs, mRNAs and miRNAs in ceRNA networks. Plasma exosomes and exosomal RNA were extracted as previously described. cDNAs of RNAs (miRNAs, IncRNAs and mRNAs) were synthesized using a Mir-X miRNA First-Strand Synthesis Kit (Takara, 638315, Japan) and PrimeScript™ RT Kit with gDNA Eraser (Takara, RR047A, Japan), respectively. Then, gene expression levels were detected by SYBR Premix Ex Taq II (RR820A) and LightCycler 480 II systems. The primers used for qRT-PCR are shown in Table 1. ACTB and U6 were used as internal reference. The relative expression levels were calculated using the 2^-ΔΔCt method, where ΔCt = Ct_target - Ct_reference, ΔΔCt = ΔCt_LAA - ΔCt_control.

Statistical Analysis

Statistical analysis was performed using SPSS (SPSS 13.0) and MedCalc software. The data are presented as the mean ± standard deviation (SD) or the medians (interquartile ranges). Independent-samples t-tests, Chi-square tests and Wilcoxon rank sum tests were used to analyze the differences between 2 groups. Logistic regression analysis was used to identify the risk factors for LAA ischemic stroke and generate the diagnostic panel. Spearman correlation analysis was used to detect relationships between RNAs. A receiver operating characteristic (ROC) curve was generated, and the area under the curve (AUC) was calculated to evaluate the diagnostic performance of differentially expressed RNAs, diagnostic panels, and diagnostic networks. p < 0.05 were considered to be statistically significant. R packages, TB Tools, and MedCalc were used for visualization of the results.

RESULTS

Basic Characteristics of the Participant Population

The basic characteristics of 35 LAA stroke patients and 35 healthy persons were shown in Table 2. There were no significant differences in sex, age, hypertension, diabetes, smoking, alcohol, and other factors.

| Variables                      | Control group | LAA group | p value |
|--------------------------------|---------------|-----------|---------|
| Sample size (%)                | 35            | 35        |         |
| Gender, number (%)             |               |           |         |
| Female                         | 16 (45.7)     | 14 (40)   | 0.629*  |
| Male                           | 19 (54.3)     | 21 (60)   |         |
| Age (years), mean ± SD         | 66.54 ± 9.21  | 65.40 ± 9.31 | 0.201†  |
| BMI (kg/m²), media (IQR)       | 22.86 (1.67)  | 22.15 (2.33) | 0.051†  |
| Diabetes, number (%)           |               |           |         |
| Yes                            | 16 (45.7)     | 14 (40)   | 0.629*  |
| No                             | 19 (54.3)     | 21 (60)   |         |
| Hypertension, number (%)       |               |           |         |
| Yes                            | 17 (48.6)     | 19 (54.3) | 0.632*  |
| No                             | 18 (51.4)     | 16 (45.7) |         |
| Smoke, number (%)              |               |           |         |
| Yes                            | 18 (51.4)     | 20 (57.1) | 0.631†  |
| No                             | 17 (48.6)     | 15 (42.9) |         |
| Alcohol, number (%)            |               |           |         |
| Yes                            | 16 (45.7)     | 15 (42.9) | 0.81*   |
| No                             | 19 (54.3)     | 20 (57.1) |         |

Data Availability Statement

Raw data files have been deposited to the Gene Expression Omnibus Database (www.ncbi.nlm.nih.gov/geo/) and accession number is GSE173719.

Then, IncRNA-related networks were established and visualized via Cytoscape.
alcohol consumption, TG, TC, LDL, and HDL between the two groups (p > 0.05).

**Identification of Plasma-Derived Exosomes**

Plasma-derived exosomes were analyzed and verified by electron microscopy, nanoparticle tracking analysis and Western blot. The presence of exosomes was confirmed by TEM, which detected cup-shaped bilayer vesicles (Figure 1A). Western blotting analysis was used to estimate the exosome purity. Three positive protein markers (CD9, CD63, and TSG101) of exosomes were all detected; conversely, GRP 94, a negative marker of exosomes, was absent from the isolated exosomes (Figure 1B). Nanoparticle tracking analysis demonstrated that the size distribution of the exosomes mainly ranged from 30–150 nm, accounting for 98.72% of the total particle number (Figure 1C). The TEM, NTA, and Western blot results were consistent with the characteristics of exosomes.

**Differential Expression Analysis**

A total of 1,020 lncRNAs were differentially expressed in the LAA group compared to the control group (Figures 2A,B), of which 226 were significantly upregulated and 794 were significantly downregulated. A total of 579 differentially expressed mRNA transcripts (Figures 2C,D) were detected, of which 255 were upregulated and 324 were downregulated. A total of 24 differentially expressed miRNAs were detected (Figures 2E,F), of which 5 were upregulated and 19 were downregulated. For lncRNAs, we screened new, previously unstudied lncRNAs for subsequent analysis. As presented in Table 3, the most upregulated lncRNA, mRNA, and miRNA were novel lnc_000288 (logFC = 20.25), FTH1 (logFC = 13.66), and hsa-miR-27 (logFC = 1.32), respectively. The most downregulated lncRNA, mRNA, and miRNA were novel lnc_000285 (logFC = −20.87), ELF1 (logFC = −11.27), and hsa-miR-
FIGURE 2 | Analysis of differently expressed RNAs. Significantly changed IncRNAs (A), mRNAs (C), and miRNAs (E) were visualized in volcano plots. Cluster heatmap of differentially expressed IncRNAs (B), mRNAs (D) and miRNAs (F). Red represents upregulated genes, and green represents downregulated genes. (G) The distributions of the differentially expressed RNAs on all 23 chromosomes. Red is the number of downregulated IncRNAs, blue is the number of upregulated IncRNA, orange is the number of downregulated mRNAs, light blue is the number of upregulated miRNAs, purple is the number of downregulated mRNAs and green is the number of upregulated mRNAs. (H) Location of TOP 20 DE IncRNAs, DE mRNAs and miRNAs on every chromosome. Red represents upregulated genes, blue represents downregulated genes, circle represents IncRNA, box represents mRNA and triangle represents miRNA.
TABLE 3 | Top 10 exo-lncRNA, exo-miRNA, exo-mRNA respectively ranked by logFC (RNA-seq data).

| Transcript Id | Gene Type     | Chr     | Length | logFC | p value   |
|---------------|---------------|---------|--------|-------|-----------|
| LNC_000288    | LincRNA       | chr11   | 889    | 20.25 | 0.00387   |
| LNC_000287    | lincRNA       | chr3    | 388    | 18.91 | 0.00375   |
| LNC_017800    | antisense_lncRNA | chr2     | 855    | 17.35 | 0.00545   |
| LNC_000291    | antisense_lncRNA | chr6     | 516    | 16.81 | 0.00593   |
| LNC_000304    | LincRNA       | chr5    | 638    | 16.56 | 0.00559   |
| LNC_000285    | lincRNA       | chr11   | 558    | 20.87 | 4.96E-05  |
| LNC_011782    | antisense_lncRNA | chr3     | 938    | 15.53 | 8.79E-06  |
| LNC_001060    | intronic_lncRNA | chr1     | 1312   | 12.92 | 0.01124   |
| LNC_001349    | lincRNA       | chr1    | 1151   | 13.75 | 0.00044   |
| LNC_000407    | lincRNA       | chr1    | 1151   | 13.68 | 0.000363  |

1277 (logFC = -1.56), respectively (Table 3, Online Supplementary Tables S1–S3).

We determined the chromosomal distribution of the differentially expressing genes (Figure 2G). The map shows that each chromosome contains differentially expressed RNAs, and chromosome 1 has the most differentially transcribed. Genes located closer to one another on chromosomes may allow similar biological functions or participate in the same metabolic pathways. We therefore also visualized the distribution of DE RNAs within each chromosome (Figure 2H).

Functional Enrichment Analysis of Differential mRNA

The main biological functions of DE mRNAs were investigated through enrichment analysis of GO and KEGG pathways to further verify the possibility of pathophysiological processes. The biological process (BP), molecular function (MF) and cellular component (CC) categories associated with DE mRNAs were displayed through a directed acyclic graph (DAG, Figures 3A–D). GO analyses showed that the pathological processes involved in LAA ischemic stroke may be regulated by DE mRNAs from different angles, such as cell-cell adhesion (GO:0098609), positive regulation of apoptotic process (GO:0043065), positive regulation of cell migration (GO:0030335), and megakaryocyte differentiation (GO:0030219). We also performed KEGG pathway analysis (Figure 3E), and the results showed that DE mRNAs were mainly related to cellular senescence (hsa04218), fluid shear stress and atherosclerosis (hsa05418), platelet activation (hsa04611), complement and coagulation cascades (hsa04610) and so on (Online Supplementary Tables S4, S5).

Construction of the Protein-Protein Interaction Network

Through PPI analysis, a network of 522 nodes and 674 edges was generated from the DE mRNAs (Figure 4A). The Cytoscape plugin MCODE was used to extract 3 submodules from the PPI network (Figures 4B–D).

1. Module1 (score = 8.667) contains 10 nodes and 40 edges, among which heterogeneous nuclear ribonucleoproteins, such as HNRNPH1, HNRNPA2B1, HNRNPF, HNRNPM, and HNRNPL (Figure 4B), were the most abundant.

2. Module 2 (score = 5.889) contains 19 nodes and 53 edges and includes AACS, CKAP5, CDK11A, and DNM3 (Figure 4C).

3. Module 3 (score = 2.571) contains 8 nodes and 9 edges and includes JUNB, BPTF, PCNA, PRRC2C, and BPTF (Figure 4D).

Construction of lncRNA-Related Molecular Networks

According to the ceRNA hypothesis, lncRNAs could influence the expression or stability of the target mRNA by binding miRNA. In this study, we selected eight hub lncRNAs, which function relates to AS and had higher fold change as well as had reads in each sample (lnc_000048, lnc_001346, lnc_001347, lnc_001350, lnc_002015, lnc_012006, lnc_013144, lnc_016442), to construct lncRNA-related networks. A total of 7274 DE lncRNAs-miRNAs pairs and 55,743 miRNAs-DE mRNAs pairs were screened out. Through the interaction of DE lncRNAs-miRNAs, DE mRNAs and DE mRNAs, 14 hub DE miRNAs (hsa-miR-1277, hsa-miR-1273h, hsa-miR-1273b, hsa-miR-1296, hsa-miR-136, hsa-miR-1538, hsa-miR-1908, hsa-miR-3127, hsa-miR-328, hsa-miR-342, hsa-miR-369, hsa-miR-381, hsa-miR-493, hsa-miR-494, hsa-miR-495) were obtained (Figure 5A).

Figure 5B reveals a downregulated DE lncRNAs–upregulated DE miRNAs-downregulated DE mRNAs regulation pattern; conversely, Figure 5C reveals the upregulated DE lncRNAs-downregulated DE miRNAs-upregulated DE mRNAs pattern.

Functional enrichment was performed to understand the biological processes of the lncRNA-related networks. The top five GO and KEGG terms were visualized in R package (Figures 5D,E). The results showed that the target genes of ceRNA networks were related to immunity, endothelial inflammation, adhesion and apoptosis. All the results confirmed lncRNAs as powerful regulatory through ceRNA mechanism in LAA stroke.
Subcellular Localization of lncRNAs

The subcellular localization of lncRNAs determines their different regulatory modes. LncRNAs can sponge their interacting miRNAs to further regulate the stability and translation of an mRNA. The positions of eight hub lncRNAs were predicted by the lncLocator and the iLoc-LncRNA website (Figure 6). Lnc_002015 and lnc_001350 are most likely to be located in the cytoplasm, which suggests that they might function through ceRNA networks.

Validation of the Differentially Expressed RNAs

We extracted 8 lncRNA-related subnetworks for subsequent analysis. The criteria for selection were as follows: coexpression of lncRNAs and mRNAs; GO and KEGG analysis of mRNAs involved in atherosclerosis. A total of 21 hub genes of networks were selected (Figure 7C). To verify our findings, we confirmed the relative expression level of 21 hub genes in the validation set (LAA: control = 30:30) by qRT-PCR (Figure 7A). The results showed that the selected genes were differentially expressed between the LAA and control groups, which were consistent with our sequencing results (Figure 7B).

Assessment of the Diagnostic Performance of the Selected exo-lncRNAs

To evaluate the diagnostic performance of the selected lncRNAs for LAA stroke, we generated ROC curves in the validation set. The diagnostic performance of lnc_000048, lnc_001346, lnc_001347, lnc_001350, lnc_002015, lnc_012006, lnc_013144,
and 0.016442, measured by the area under the curve (AUC), were 0.78, 0.791, 0.806, 0.751, 0.818, 0.842, and 0.705, respectively (Figure 8).

**Correlation Between the 21 hub RNAs and Clinical Characteristics**

We analyzed the correlation between the 21 exo-hub genes. The results showed that the correlations of the 21 exo-hub genes were consistent with our predicted outcomes. As shown in Figure 9A, selected upregulated lncRNAs were negatively correlated with miRNAs (hsa-miR-342, hsa-miR-1273, hsa-miR-328) and coexpressed with mRNAs (JUNB, AACS, ST14). Furthermore, the analysis in combination with clinical outcomes demonstrated that upregulated exo-hub RNAs acted as risk factors for LAA stroke (Figure 9B).

**Exploration of the exo-lncRNA-related Diagnostic Model of LAA Stroke**

Combining risk factors may improve their diagnostic accuracy. Therefore, logistic regression analysis was performed to establish a diagnostic panel of the hub exosomal lncRNAs (lnc_000048, lnc_001346, lnc_001347, lnc_001350, lnc_002015, lnc_012006, lnc_013144, lnc_016442). The results showed that lnc_001350 (OR: 2.038, \( p < 0.05 \)) promoted the onset of LAA stroke, whereas lnc_002015 (OR: 0.017, \( p < 0.005 \)) was a protective factor. The probability of being diagnosed with LAA stroke was calculated using the following equation: Logit (P) = 1.127 + 0.712 × lnc_001350 - 4.07 × lnc_002015. The AUC of the predicted diagnostic panel was 0.918 (95% CI = 0.827–0.970, Figure 10A). However, the difference in AUC between lnc_002015 (0.863) and the panel (0.918) was not statistically significant (\( p = 0.085 \)).

LncRNAs could be integrated with mRNAs and miRNAs as possible biomarkers for disease diagnosis. Further, the exo-lncRNA (lnc_002015 and lnc_001350), which belongs to the factors of Logistic regresson diagnostic panel, related networks were analyzed by ROC analysis. The results showed that the AUCs of the lnc_002015-related network and lnc_001350-related network were 0.959 (95% CI = 0.883–0.992, Figure 10E, 0.970) (95% CI = 0.898–0.996, Figure 10I), respectively. Although combining two compositions of the network randomly could improve the diagnostic performance (Figures...
FIGURE 5 | The IncRNAs-miRNAs-mRNAs networks and functional analysis. (A) The interaction of DE IncRNAs-miRNAs pairs, miRNAs-DE mRNAs pairs and DE miRNAs. (B) downregulated IncRNAs-upregulated miRNAs-downregulated mRNAs networks. (C) upregulated IncRNAs-downregulated miRNAs-upregulated mRNAs networks. Triangles represent miRNAs, circles represent mRNAs, squares with purple edges represent IncRNAs, green represents downregulated RNAs, and pink represents upregulated RNAs. (D) GO analysis of mRNAs in the networks. (E) KEGG analysis of mRNAs in the networks. Red represents upregulated mRNAs, and blue represents downregulated mRNAs.
the network showed an obvious advantage over each combination in identifying LAA stroke patients. The differences between the AUCs of the network and each factor in the network were statistically significant ($p < 0.05$), which indicated that the exo-lncRNA-related networks might have higher diagnostic efficacy.

**DISCUSSION**

This is the first study to comprehensively analyze circulating exosomal lncRNA sequencing in LAA stroke and control. We determined the differential expression profile of exosomal lncRNAs and built lncRNA-related networks. The results showed that lncRNA-related networks exhibited better diagnostic performance than single factor, and these networks might be considered promising diagnostic models and provide novel insights into the mechanism in LAA stroke.

Exosomes protect lncRNAs from RNase-induced damage to maintain the concentration of lncRNAs in the blood (Guo et al., 2020; Kim et al., 2020), and the stability of exosomal lncRNAs makes them good potential diagnostic biomarkers. Hu et al. reported that the expression level of plasma exosomal lncRNAs was significantly upregulated in colorectal cancer patients, serving as biomarkers for the early detection of CRC (Hu et al., 2018). Kenji Takahashi et al. highlighted that highly upregulated circulating exosome-encapsulated lncRNAs were potential biomarkers of pancreatic cancer (Takahashi et al., 2020). Our current findings showed that exo-lncRNAs were significantly differentially expressed in our discovery samples. Furthermore, the results were verified by validation samples, which suggested that these exo-lncRNAs might have diagnostic potential in LAA stroke.

Recently, lncRNAs have been studied because they can regulate mRNA expression in many forms, including through competitive binding with miRNAs (Cesana et al., 2011). Through their interactions with the seed regions of miRNAs, lncRNAs can block an entire family of related miRNAs. This leads to the disinhibition of downstream target genes, ensuring the stability of the mRNA function (Huang et al., 2019). Le Qu et al. found that lncARSR could promote c-MET and AXL expression by acting as a ceRNA for miR-449 and miR-34 in renal cancer. Similarly, our study found that exo-lncRNA could bind one or more miRNAs and regulate multiple mRNAs, which was consistent with previous research.

Furthermore, functional enrichment (GO and KEGG pathway) analysis was performed on the target genes (mRNAs) of lncRNA-related networks. The results showed that lncRNA-related networks were involved in inflammation, cell adhesion, immunity and other functions. For instance, GO: 0050839, representing cell adhesion, has been proven to be related to atherosclerosis. Chadjichristos CE found that Cx40 promotes leukocyte adhesion to the endothelium and accelerates atherosclerosis (Chadjichristos et al., 2010). GO: 0006979, representing response to oxidative stress, also participates in atherosclerosis. Chen Y et al. revealed that fatty acid metabolism is disordered in response to oxidative stress from the mitochondria, which drives chronic inflammation and accelerates the process of atherosclerosis (Chen et al., 2015). Therefore, we speculated that the DE lncRNAs might regulate the progression of LAA stroke by targeting genes.

According to the functional annotation results, we selected eight lncRNAs that might be related to atherosclerosis. Based on ceRNA theory, we constructed eight lncRNA-related networks, such as Inc_002015/hsa-mir-342/PTPRC/AAMP and Inc_001350/hsa-mir-3127/ST14. PTPRC, protein tyrosine phosphatase receptor type C, is a signaling molecule that regulates a variety of biological processes, including cell growth, differentiation and mitosis (Bottero et al., 2018). Recently, Pan et al. (2020) found that PTPRC was associated with atherosclerosis as a hub gene in...
the regulation of cell cycle progression. MiR-342 directly targets Akt1 through its 3'UTR region and induces the downregulation of proinflammatory factors such as Nos2 and IL-6. Thus, miR-342 promotes the progression of atherosclerosis in Apoe/mice (Wei et al., 2013). The above two genes are related to the progression of atherosclerosis, implying that lnc_002015, as an important member of the ceRNA mechanism, has potential regulatory capacity in LAA stroke. This is the first study to imply that lnc_002015 might act as a molecular sponge of miR-342 to regulate the progression of atherosclerosis. More experiments are needed to explore the pathways of genes and the functions of this network.

Importantly, the logistic regression model revealed that lnc_001350 was positively associated with the risk of LAA...
stroke, whereas lnc_002015 was predicted as a protective factor. The diagnostic performance of lnc_002015 was consistent with the functional enrichment of the lnc_002015-related network. ROC curves revealed that all the selected exosomal hub genes had the potential to be diagnostic indicators.

To elevate the accuracy of diagnosis, we performed ROC analysis on the panel of the logistics equation and the corresponding exo-lncRNA related networks simultaneously and compared them. Interestingly, the AUCs all changed obviously when we integrated factors from both the regression equation and ceRNA networks into the analysis concurrently. However, there was no statistically significant difference between the diagnostic performances of the diagnostic panel and each factor in the panel. In contrast,
exo-lnc_002015- and exo-lnc_001350-related networks showed improved diagnostic performance, which might due to the interactions among the genes. The results implied that the diagnostic possibilities of exo-lncRNA-related networks were higher than those of single factors in LAA stroke. Future validation of individual exo-lncRNA-related networks in a larger cohort is needed.

In conclusion, this study has clarified the differentially expressed exosomal IncRNAs in LAA stroke. More importantly, the results showed for the first time that the
diagnostic performance of the exo-IncRNA-related network is superior to that of single factor, which might serve as a novel and accurate diagnostic method. Our findings may offer new perspectives to explore candidate targets for the diagnosis and mechanism of LAA stroke.

**DATA AVAILABILITY STATEMENT**

The data presented in the study are deposited in the (GEO) repository, accession number (GSE173719).

**ETHICS STATEMENT**

The studies involving human participants were reviewed and approved by the Ethics Committee of The Affiliated Hospital of Qingdao University. The patients/participants provided their written informed consent to participate in this study.

**AUTHOR CONTRIBUTIONS**

SZ and XZ designed the study. SZ, JW, MQ, KW, and XZ collected the literature. SZ and XZ performed statistical analyses. SZ, JW, MQ, KW, XZ, AM, and XP analyzed the data. SZ and XZ wrote the manuscript. All authors read and approved the final manuscript.

**REFERENCES**

Adams, H. P., Bendixen, B. H., Kappelle, L. J., Biller, J., Love, B. B., Gordon, D. L., et al. (1993). Classification of Subtype of Acute Ischemic Stroke. Definitions for Use in a Multicenter Clinical Trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 24 (1), 35–41. doi:10.1161/01.str.24.1.35

Al-Nedawi, K., Meehan, B., Micallef, J., Lhotak, V., May, L., Guha, A., et al. (2008). Intercellular Transfer of the Oncogenic Receptor EGFRvIII by Microvesicles Derived from Tumour Cells. Nat. Cell Biol 10 (5), 619–624. doi:10.1038/nclb1725

Bottero, V., Santiago, J. A., and Potashkin, J. A. (2018). PTPRC Expression in Blood Is Downregulated in Parkinson’s and Progressive Supranuclear Palsy Disorders. J. Parkinsons Dis. 8 (4), 529–537. doi:10.3233/jpd-181391

Cesana, M., Cacciarelli, D., Legnini, I., Santini, T., Sthandier, O., Chinappi, M., et al. (2011). A Long Noncoding RNA Controls Muscle Differentiation by Functioning as a Competing Endogenous RNA. Cell 147 (2), 358–369. doi:10.1016/j.cell.2011.09.028

Chadjichristos, C. E., Scheidenbach, K. E. L., van Veen, T. A. B., Richani Sarieddine, M. Z., de Wit, C., Yang, Z., et al. (2010). Endothelial-specific Deletion of Connexin40 Promotes Atherosclerosis by Increasing CD73-dependent Leukocyte Adhesion. Circulation 121 (1), 123–131. doi:10.1161/circulationaha.109.867176

Chen, X.-L., Li, Q., Huang, W.-S., Lin, Y.-S., Xue, J., Wang, B., et al. (2017). Serum YKL-40, a Prognostic Marker in Patients with Large-Artery Atherosclerotic Stroke. Stroke 48 (15), 41. doi:10.1161/strokeaha.119.025732

Guo, X., Ly, X., Ru, Y., Zhou, F., Wang, N., Xi, H., et al. (2020). Circulating Exosomal Gastric Cancer-Associated Long Noncoding RNA1 as a Biomarker for Early Detection and Monitoring Progression of Gastric Cancer. JAMA Surg. 155 (7), 572–579. doi:10.1001/jamasurg.2020.1133

Hu, D., Zhan, Y., Zhu, K., Bai, M., Han, J., Si, Y., et al. (2018). Plasma Exosomal Long Non-coding RNAs Serve as Biomarkers for Early Detection of Colorectal Cancer. Cell Physiol. Biochem. 51 (6), 2704–2715. doi:10.1159/000495961

Huang, W., Li, Q., Chen, X., Lin, Y., Xue, J., Cai, Z., et al. (2017). Soluble Lectin-like Oxidized Low-Density Lipoprotein Receptor-1 as a Novel Biomarker for Large-Artery Atherosclerotic Stroke. Int. J. Neurosci. 127 (10), 881–886. doi:10.1080/00207454.2016.1272601

Huang, Y., Xu, Y., Lu, Y., Zhu, S., Guo, Y., Sun, C., et al. (2019). IncRNA Gm10451 Regulates PTIP to Facilitate iPSCs-Derived β-Cell Differentiation by Targeting miR-338-3p as a ceRNA. Biomaterials 216, 119266. doi:10.1016/j.biomaterials.2019.119266

Jeppesen, D. K., Fenix, A. M., Franklin, J. L., Higginbotham, J. N., Zhang, Q., Zimmerman, L. J., et al. (2019). Reassessment of Exosome Composition. Cell 177 (2), 428–445. e418. doi:10.1016/j.cell.2019.02.029

Jia, L., Zhu, M., Kong, C., Pang, Y., Zhang, H., Qiu, Q., et al. (2021). Blood Neuro-exosomal Synaptic Proteins Predict Alzheimer’s Disease at the Asymptomatic Stage. Alzheimer’s Dement. 17 (1), 49–60. doi:10.1002/alz.12166

Khalyfa, A., Gozal, D., Chan, W.-C., Andrade, J., and Prasad, B. (2020). Circulating Plasma Exosomes in Obstructive Sleep Apnoea and Reverse Dipping Blood Pressure. Eur. Respir. J. 55 (1), 1901072. doi:10.1183/13993003.01072-2019

Kim, S., Baek, G., Ahn, H., Sung, S., Seo, C., Cho, H., et al. (2020). Serum Small Extracellular Vesicle-Derived LINCO00853 as a Novel Diagnostic Marker for Early Hepatocellular Carcinoma. Mol. Oncol. 14 (10), 2646–2659. doi:10.1002/1878-0261.12745

Lansberg, M. G., Bluhmki, E., and Thijs, V. N. (2009). Efficacy and Safety of Tissue Plasminogen Activator 3 to 4.5 Hours after Acute Ischemic Stroke. Stroke 40 (7), 2438–2441. doi:10.1161/strokeaha.109.552547
Lobb, R. J., Becker, M., Wen Wen, S., Wong, C. S. F., Wiegman, A. P., Leimgruber, A., et al. (2015). Optimized Exosome Isolation Protocol for Cell Culture Supernatant and Human Plasma. *J. extracellular vesicles* 4, 27031. doi:10.3402/jev.v4.27031

Lu, Y., Duan, Y., Xu, Q., Zhang, L., Chen, W., Qu, Z., et al. (2020). Circulating Exosome-derived Bona Fide Long Non-coding RNAs Predicting the Occurrence and Metastasis of Hepatocellular Carcinoma. *J. Cell Mol Med* 24 (2), 1311–1318. doi:10.1111/jcmm.14783

Murat Sumer, M., Erturk, O., and Neurophysiology, o. t. I. S. o. C. (2002). Ischemic Stroke Subtypes: Risk Factors, Functional Outcome and Recurrence. *Neuro. Sci.* 22 (6), 449–454. doi:10.1007/s100720200004

Pan, Y., Yu, C., Huang, J., Rong, Y., Chen, J., Chen, M., et al. (2020). Bioinformatics Analysis of Vascular RNA-Seq Data Revealed Hub Genes and Pathways in a Novel Tibetan Minipig Atherosclerosis Model Induced by a High Fat/cholesterol Diet. *Lipids Health Dis.* 19 (1), 54. doi:10.1186/s12944-020-01222-w

Qin, C., Xie, Y., Wang, Y., Li, S., Ran, C., He, S., et al. (2018). Impact of Lactobacillus Casei BL23 on the Host Transcriptome, Growth and Disease Resistance in Larval Zebrafish. *Front. Physiol.* 9, 1245. doi:10.3389/fphys.2018.01245

Qu, L., Ding, J., Chen, C., Wu, Z.-J., Liu, B., Gao, Y., et al. (2016). Exosome-Transmitted IncARSR Promotes Sunitinib Resistance in Renal Cancer by Acting as a Competing Endogenous RNA. *Cancer cell* 29 (5), 653–668. doi:10.1016/j.ccell.2016.03.004

Robinson, E. K., Covarrubias, S., and Carpenter, S. (2020). The How and Why of IncRNA Function: An Innate Immune Perspective. *Biochim. Biophys. Acta (Bba) - Gene Regul. Mech.* 1863 (4), 194419. doi:10.1016/j.bbagrm.2019.194419

Serghiou, S., Kyriakopoulou, A., and Ioannidis, J. P. A. (2016). Long Noncoding RNAs as Novel Predictors of Survival in Human Cancer: a Systematic Review and Meta-Analysis. *Mol. Cancer* 15 (1), 50. doi:10.1186/s12943-016-0535-1

Shen, Y., Peng, C., Bai, Q., Ding, Y., Yi, X., Du, H., et al. (2019). Epigenome-Wide Association Study Indicates Hypomethylation of MTRNR2L8 in Large-Artery Atherosclerosis Stroke. *Stroke* 50 (6), 1330–1338. doi:10.1161/strokeaha.118.023436

Sidorov, E., Sanghera, D. K., and Vanamala, J. K. P. (2019). Biomarker for Ischemic Stroke Using Metabolome: A Clinician Perspective. *J. Stroke* 21 (1), 31–41. doi:10.5853/jos.2018.03454

Takahashi, K., Ota, Y., Kogure, T., Suzuki, Y., Iwamoto, H., Yamakita, K., et al. (2020). Circulating Extracellular Vesicle-encapsulated HULC Is a Potential Biomarker for Human Pancreatic Cancer. *Cancer Sci.* 111 (1), 98–111. doi:10.1111/cas.14232

Tian, S., Zhou, X., Phuntsok, T., Zhao, N., Zhang, D., Ning, C., et al. (2020). Genomic Analyses Reveal Genetic Adaptations to Tropical Climates in Chickens. *Science* 23 (11), 101644. doi:10.1163/01644

Wei, Y., Nazari-Jahantigh, M., Chan, L., Zhu, M., Heyll, K., Corbalán-Campos, J., et al. (2013). The microRNA-342-5p Fosters Inflammatory Macrophage Activation through an Akt1- and microRNA-155 -Dependent Pathway during Atherosclerosis. *Circulation* 127 (15), 1609–1619. doi:10.1161/circulationaha.112.00736

Zhan, Y., Du, L., Wang, L., Jiang, X., Zhang, X., Zhang, S., Li, J., et al. (2018). Expression Signatures of Exosomal Long Non-coding RNAs in Urine Serve as Novel Non-invasive Biomarkers for Diagnosis and Recurrence Prediction of Bladder Cancer. *Mol. Cancer* 17 (1), 142. doi:10.1186/s12943-018-0893-y

Zhang, H., Chen, G., Qiu, W., Pan, Q., Chen, Y., Chen, Y., et al. (2020). Plasma Endothelial Microvesicles and Their Carrying miRNA-155 Serve as Biomarkers for Ischemic Stroke. *J. Neurosci. Res.* 98 (11), 2290–2301. doi:10.1002/jnr.24696

Zheng, M., Hou, L., Ma, Y., Zhou, L., Wang, F., Cheng, B., et al. (2019). Exosomal Let-7d-3p and miR-30d-5p as Diagnostic Biomarkers for Non-invasive Screening of Cervical Cancer and its Precursors. *Mol. Cancer* 18 (1), 76. doi:10.1186/s12943-019-0999-x

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Zhang, Wang, Qu, Wang, Ma, Pan and Zhu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.